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Growing evidence supports the role of gut microbiota in the development of obesity, type
2 diabetes, and low-grade inﬂammation.The endocrine activity of adipose tissue has been
found to contribute to the regulation of glucose homeostasis and low-grade inﬂammation.
Among the key hormones produced by this tissue, apelin has been shown to regulate
glucose homeostasis. Recently, it has been proposed that gut microbiota participate in adi-
pose tissue metabolism via the endocannabinoid system (eCB) and gut microbiota-derived
compounds, namely lipopolysaccharide (LPS). We have investigated gut microbiota com-
position in obese and diabetic leptin-resistant mice (db/db) by combining pyrosequencing
and phylogenetic microarray analysis of 16S ribosomal RNA gene sequences.We observed
a signiﬁcant higher abundance of Firmicutes, Proteobacteria, and Fibrobacteres phyla in
db/db mice compared to lean mice.The abundance of 10 genera was signiﬁcantly affected
by the genotype.We identiﬁed the roles of the eCB and LPS in the regulation of apelinergic
system tone (apelin and APJ mRNA expression) in genetic obese and diabetic mice. By
using in vivo and in vitro models, we have demonstrated that both the eCB and low-grade
inﬂammation differentially regulate apelin and APJ mRNA expression in adipose tissue.
Finally, deep-gut microbiota proﬁling revealed that the gut microbial community of type 2
diabetic mice is signiﬁcantly different from that of their lean counterparts. This indicates
speciﬁc relationships between the gut microbiota and the regulation of the apelinergic
system. However, the exact roles of speciﬁc bacteria in shaping the phenotype of db/db
mice remain to be determined.
Keywords: gut microbiota, type 2 diabetes, inﬂammation, LPS, endocannabinoid, apelin, APJ, metabolic
endotoxemia
INTRODUCTION
Obesity and associated metabolic disorders (e.g., insulin resis-
tance, type 2 diabetes, and cardiovascular diseases) are closely
associated with a low-grade inﬂammatory state (Olefsky and
Glass, 2010). Numerous studies have proposed that, in obese
conditions, both the endocrine activity of adipose tissue and
macrophage inﬁltration participate in the development of a low-
grade inﬂammatory tone (Olefsky and Glass, 2010). Compelling
evidence supports the idea that adipokines participate in the
regulation of glucose homeostasis and low-grade inﬂammation
(Deng and Scherer, 2010; Federico et al., 2010). Among the
recently discovered adipokines, apelin has been proposed as a
novel key peptide involved in the regulation of several physio-
logical functions. Apelin and APJ mRNA are widely expressed
in mammals and exert functional effects in both the central
nervous system and the periphery (Sorli et al., 2006). Apelin
plays a key role in the cardiovascular system by acting on heart
contractility, blood pressure, ﬂuid homeostasis, vessel forma-
tion, and cell proliferation (Maenhaut and Van, 2011). Apelin
serum levels are linked to the nutritional status and plasma
insulin levels in both rodents and humans (Dray et al., 2008;
Duparc et al., 2011a). Furthermore, apelin plasma concentra-
tions are increased in obese subjects and in hyperinsulinemic
obese mice compared to lean subjects (Dray et al., 2010). Inter-
estingly, apelin has been shown to control glucose homeosta-
sis by AMP-kinase- and nitric oxide (NO)-dependent mecha-
nisms (Dray et al., 2008; Duparc et al., 2011b). Recently, it has
been proposed that inﬂammation could participate in the pro-
duction of apelin and the modulation of its receptor expres-
sion (Daviaud et al., 2006; Han et al., 2008a,b). Nevertheless,
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the mechanisms involved in the regulation of apelin and its
speciﬁc G protein-coupled receptorAPJ have not been completely
elucidated.
Growing evidence supports the role of gut microbiota in the
development of obesity, type 2 diabetes, insulin resistance, and
low-grade inﬂammation (Backhed et al., 2004; Ley et al., 2006;
Turnbaugh et al., 2006; Cani et al., 2007a, 2008, 2009; Martinez
et al., 2009; Vijay-Kumar et al., 2010). However, the composition
of the gut microbiota and the exact role of the microorganisms
presentinthegutremainpoorlydeﬁned.Nonetheless,advancesin
culture-independent methods for characterizing microbial diver-
sity have helped to evaluate the functional contribution of this
large collection of microbes in host metabolism (Martin et al.,
2008;Turnbaughetal.,2009).Forinstance,recentdatasuggestthat
changes in gut microbiota composition and gut barrier functions
playacriticalroleinthedevelopmentofobesity-associatedinﬂam-
mation(Brunetal.,2007;Canietal.,2008,2009;DeLaSerreetal.,
2010).Accordingly,wehaveproposedthatobesity-associatedlow-
grade inﬂammation and adipogenesis processes may be related to
thegutmicrobiotabymechanismsinvolvingtheendocannabinoid
system (eCB) and bacterially derived lipopolysaccharide (LPS;
Cani et al., 2007a,b, 2008, 2009; De La Serre et al., 2010; Muccioli
et al.,2010).
The eCB system is composed of endogenous lipids that
activate speciﬁc G protein-coupled receptors termed cannabi-
noid receptors 1 and 2 (CB1 and CB2). Among these
lipids, N-arachidonoylethanolamine (anandamide, AEA), and
2-arachidonoylglycerol (2-AG) are the most studied (Lambert
and Muccioli, 2007). AEA and 2-AG are both widely present
throughout the body, and their tissue levels are regulated by
the balance between synthesis and inactivation. Brieﬂy, N-
acylphosphatidylethanolamines (NAPEs) are precursors for AEA
throughtheactivityofN-acylphosphatidylethanolamine-selective
phospholipase-D (NAPE-PLD),whereas 2-AG can be synthesized
mainly through diacylglycerol lipase (DAGL; Muccioli, 2010).
Compelling strong evidence has shown that dysregulation of the
tight control of endocannabinoid levels may result in pathologi-
cal situations such as obesity and related metabolic syndromes or
neurological disorders (Lambert and Muccioli, 2007). The main
enzymes responsible for their degradation are fatty acid amide
hydrolase(FAAH;Cravattetal.,1996)andmonoacylglycerollipase
(MGL;Dinhetal.,2002),respectively.Obesityandtype2diabetes
are associated with greater eCB system tone (altered expression
of NAPE-PLD, CB1 mRNA, and higher eCB levels in plasma or
adipose tissue; Muccioli et al., 2010). Moreover, LPS is known to
stimulate eCB synthesis (Liu et al., 2003; Muccioli et al., 2010),
and the gut microbiota participate in this complex regulation
(Muccioli et al.,2010).
Although changes in the gut microbiota of obese mice (ob/ob)
or mice with high-fat diet-induced obesity were clearly demon-
strated (Ley et al., 2005; Cani et al., 2007a,b; Turnbaugh et al.,
2008,2009;Hildebrandt et al.,2009),the exact composition of the
gutmicrobiotaof type2diabeticmice(db/db)remainsunknown.
In light of these recent ﬁndings,we also decided to investigate the
potential implication of these three key players (eCB, LPS, and
the gut microbiota) in the regulation of apelin and APJ expres-
sioninadiposetissue.Therefore,wecombinedmultiplemolecular
methods, including bar-coded pyrosequencing and phylogenetic
microarrayanalysisof 16SribosomalRNA(rRNA)genes,tocom-
pare the gut microbial communities in genetic obese and diabetic
micewiththeirleanlittermates.Thedatapresentedhereindemon-
strated that apelin and APJ expression were down-regulated by
the eCB in physiological conditions and were up-regulated by
the bacteria-derived compound LPS in pathological situations. In
addition, gut microbiota proﬁling revealed speciﬁc relationships
between the gut microbiota and regulation of the apelinergic sys-
tem and also potential novel bacterial targets that are essential to
the host metabolism.
MATERIALS AND METHODS
MICE
Six-week-old db/db mice or lean littermates (n =6/group;
C57BL/6background,Jackson-Laboratory,BarHarbor,ME,USA)
were housed in a controlled environment (12-h daylight cycle,
lights-off at 6-pm) in groups of two mice/cage. Both groups
of mice were given free access to similar control diet (A04,
Villemoisson sur Orge, France) and tap water for 1week.
All mouse experiments were approved by and performed in
accordance with the guidelines of the local ethics committee.
Housing conditions were speciﬁed by the Belgian Law of Novem-
ber 14, 1993, regarding the protection of laboratory animals
(agreement number LA1230314).
TISSUE SAMPLING
Seven-week-old mice were anesthetized by intraperitoneal injec-
tion of 100mg/kg ketamine and 10mg/kg xylazine after a 5-h
fasting period. Blood samples were harvested for further analysis.
Mice were sacriﬁced by cervical dislocation. Subcutaneous adi-
pose deposits were dissected and immediately immersed in liquid
nitrogen and stored at −80˚C for further analysis.
PLASMA APELIN
Apelin was measured using an Apelin EIA kit (Phoenix peptides)
according to the manufacturer’s instructions.
MEASUREMENT OF ANANDAMIDE (AEA) TISSUE LEVELS.
Tissues were homogenized in CHCl3 (10ml), and a deuterated
standard(d-AEA;200pmol)wasadded.Methanol(5ml)andH2O
(2.5ml) were added, and lipids were then extracted by vigorous
mixing.Followingcentrifugation,theorganiclayerwasrecovered,
dried under a stream of N2 and puriﬁed by solid-phase extrac-
tionusingsilica,followedbyelutionwithanEtOAc–Acetone(1:1)
solution (Muccioli and Stella, 2008; Muccioli et al., 2010). The
resulting lipid fraction was analyzed by HPLC–MS using an LTQ
Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc) coupled
to an Accela HPLC system (Thermo Fisher Scientiﬁc). Analyte
separationwasachievedusingaC-18Supelguardpre-columnand
a Supelcosil LC-18 column (3μM, 4×150mm; Sigma-Aldrich).
Mobile phases A and B were composed of MeOH–H2O–acetic
acid75:25:0.1(v/v/v)andMeOH–aceticacid100:0.1(v/v),respec-
tively. The gradient (0.5ml/min) was designed as follows: transi-
tion from 100% A to 100% B linearly over 15min, followed by
10min at 100% B and subsequent re-equilibration at 100%A.We
performed MS analysis in the positive mode with anAPCI ioniza-
tion source. The capillary and APCI vaporizer temperatures were
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set at 250 and 400˚C, respectively. Anandamide was quantiﬁed
by isotope dilution using its respective deuterated standard with
identical retention. The calibration curves were generated as pre-
viously described (Muccioli and Stella, 2008), and the data were
normalized by tissue sample weight.
DNA ISOLATION FROM MOUSE CECAL SAMPLES
The cecal contents of mice collected post mortem were stored at
−80˚C. Metagenomic DNA was extracted from the cecal con-
tents (ﬁve db/db and ﬁve lean) using a QIAamp DNA Stool Mini
kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Two cecal contents were not included in further gut
microbiota analyses for technical reasons.
16S RRNA GENE AMPLIFICATION AND SEQUENCING
For each sample, we ampliﬁed the V1–3 region of the bac-
terial 16S rRNA gene corresponding to Escherichia coli 16S
rRNA gene positions 28–514, excluding primer sequences. PCRs
included 1μlo f5 0 × diluted puriﬁed DNA,0.5μMo ff o r w a r dB -
8fhomd (5 -gccttgccagcccgctcag-ac-GAGTTTGATCMTGGCTCA
G-3 ), 0.05μM of forward B-8f-Biﬁdo (5 -gccttgccagcccgctcag-
ac-AGGGTTCGATTCTGGCTCAG-3 ), and 0.5μM of a bar-
codedreverseA-534RhomdDEGaprimer(5 -gcctccctcgcgccatcag-
NNNNNNNN-at-CCGCGGCTGCTGGCAC-3 )i n5 0 μlo f
PrimeStarHSPremix(Takara).Theseprimersincluded(i)the454
Life Science 19-base adaptorsA (lowercase underlined) or B (low-
ercase plain); (ii) an eight-base sample-speciﬁc barcode sequence
(NNNNNNNN; designated 692–701 in Hamady et al. (2008);
Table A1); (iii) the sequence of the broad-range 16S forward or
reverseprimer(uppercase);and(iv)adinucleotidesequence(low-
ercase italic) introduced between the 16S primer and the barcode
sequence designed to prevent pairing of different barcodes with
rDNA targets.
PCRs were performed for 29 cycles at 98˚C for 10s, 56˚C for
15s, and 72˚C for 1min. One microliter of the sample was run
on the Agilent 2100 Bioanalyzer using a DNA1000 lab chip to
conﬁrm the proper size. Two replicate reactions were pooled and
cleaned using the QIAquick PCR puriﬁcation kit (Qiagen). DNA
concentration was assessed using a NanoDrop 1000 spectropho-
tometer. One hundred nanograms of each of the puriﬁed samples
were pooled and sequenced on a Genome Sequencer FLX system
(Roche).
Bar-coded 16S rDNA amplicons associated with several unre-
lated projects were included in the same sequencing run. A total
of 39,548 reads, which had a quality score <20, corresponded to
cecal samples from the 10 mice presented in this study.
INFORMATIC ANALYSIS
Sequences containing uncalled bases, incorrect primer sequences
orrunsof ≥10identicalnucleotideswereremoved.Readswiththe
16SrDNAforwardoligonucleotidesequenceCCGCGRCTGCTG-
GCGC, containing G instead of A at the penultimate position of
the3  end,werelikelyduetoaprimersynthesisorsequencingarti-
fact(Lazarevicetal.,2010)andwerenotremovedfromthedataset
provided other quality criteria were met. After trimming primer
sequences, reads <200 or >290nt and those that incompletely
covered the E. coli 16S rRNA gene positions 288–514,determined
using the RDP pyrosequencing tool Aligner (Cole et al., 2009),
were discarded, leaving 31,577 sequences. Sequences were exam-
ined for potential chimeras using the MG-RAST server (Meyer
et al.,2008).
Sequences were assigned to representative phylotypes at 97%
identity (97%-ID phylotypes) using CD-HIT (Huang et al.,
2010). Distances between 97%-ID phylotypes aligned by MUS-
CLE (Edgar, 2004) were calculated using FastTree (Price et al.,
2009). Hierarchical clustering and principal coordinates analyses
were performed using UniFrac (Lozupone et al., 2006). The taxo-
nomic composition was assigned using the RDP Classiﬁer (Wang
et al., 2007) with a recommended 50% conﬁdence cut-off. The
sequences (31,577 reads) are publicly available at the MG-RAST
repository (Meyer et al., 2008) under ID 4455129.
MITCHIP: PCR PRIMERS AND CONDITIONS
The Mouse Intestinal Tract Chip (MITChip) is a phy-
logenetic microarray consisting of 3,580 different oligonu-
cleotides speciﬁc for the mouse intestinal microbiota (Derrien
et al., in preparation). Both the design and analysis of
the MITChip were performed as previously described for
the human counterpart (Rajilic-Stojanovic et al., 2009). In
short, 20ng of cecal DNA extract was used to amplify the
16S rRNA genes with the primers T7prom-Bact-27-for (5 -T
GAATTGTAATACGACTCACTATAGGGgtttgatcctggctcag-3 ) and
Uni-1492-rev (5 -CGGCTACCTTGTTACGAC-3 ). Subsequently,
an in vitro transcription and labeling with Cy3 and Cy5 dyes was
performed. Fragmentation of Cy3/Cy5-labeled target mixes was
followedbyhybridizationonthearraysat62.5˚Cfor16hinarota-
tion oven (Agilent Technologies, Amstelveen, The Netherlands).
The slides were washed and dried before scanning. Signal inten-
sity data were obtained from the microarray images using Agilent
FeatureExtractionsoftware,version9.11.Microarraydatanormal-
izationandfurtheranalysiswereperformedusingasetof R-based
scripts2 in combination with a custom-designed relational data-
base12, which operates under the MySQL database management
system3.
RNA PREPARATION AND REAL-TIME QPCR ANALYSIS
Total RNA was prepared from tissues using TriPure reagent
(Roche). Quantitation and integrity analysis of total RNA
was performed by running 1μl of each sample on an Agi-
lent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit, Agilent).
cDNA was prepared by reverse transcription of 1μg total
RNA using a Reverse Transcription System kit (Promega, Lei-
den, The Netherlands). Real-time PCRs were performed with
the StepOnePlus™ real-time PCR system and software (Applied
Biosystems, Den Ijssel, The Netherlands) using Mesa Fast qPCR™
(Eurogentec, Seraing, Belgium) for detection according to the
manufacturer’s instructions. RPL-19 RNA was chosen as the
housekeeping gene. Primer sequences for RPL-19, IL-1, F4-
80, CD68, MCP-1, TNF-α, Apelin, APJ, CB1, MGL, FAAH,
and NAPE-PLD were previously described (Cani et al., 2008,
1http://www.agilent.com
2http://r-project.org
3http://www.mysql.com
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2009; Dray et al., 2008; Muccioli, 2010). The primer sequences
for CD11c were F-ACG-TCA-GTA-CAA-GGA-GAT-GTT-GGA
and R-ATC-CTA-TTG-CAG-AAT-GCT-TCT-TTA-CC. All sam-
ples were run in duplicate in a single 96-well reaction plate,
and data were analyzed according to the 2− CT method. The
identity and purity of the ampliﬁed product was checked
through analysis of the melting curve carried out at the end of
ampliﬁcation.
ADIPOSE TISSUE EXPLANT CULTURES
Subcutaneous adipose depots from 10 C57BL/6J (wild-type lean)
mice were precisely dissected, and all visible vessels, particles,
and conjunctive tissue were removed. The fat tissue was then cut
with scissors into small pieces (4mm3), pooled, and placed in
Krebs buffer (pH 7.4) containing 2% (w/v) fatty acid-free BSA,
penicillin (100IU/ml), streptomycin (100μg/ml), and ampho-
tericin B (2.5μl/ml; Invitrogen). A total of 250mg of adipose
tissue was rinsed in phosphate-buffered saline and incubated in
100-mm Petri dishes containing 10ml MEM with Earle’s salts
(Invitrogen) supplemented with 0.5% fatty acid-free BSA, peni-
cillin (100IU/ml), streptomycin (100μg/ml), and amphotericin
B (2.5μl/ml; Invitrogen). All conditions were repeated in four to
ﬁvedifferentdishes(n =4–5).Thedisheswereculturedfor24hat
37˚Cina5%CO2 atmosphere.Thebasalconcentrationof glucose
in fresh media was 5mmol/l, whereas the basal levels of cortisol
andinsulinwereextremelylow(∼0.5nmol/land3pmol/l,respec-
tively). Different pharmacological agents were used in various
combinations in accordance with the experimental protocols. LPS
(E. coli 055:B5, 100ng/ml, Sigma) and HU-210 (100nM, Tocris)
were diluted in DMSO, which also served as a control. Cell via-
bility did not change over the course of the experiment (data not
shown). At the end of the experiment, the adipose material was
rinsedinphosphate-bufferedsaline,collected,immediatelyfrozen
in liquid nitrogen, and stored at −80˚C until subsequent mRNA
analysis.
STATISTICAL ANALYSES
The data are expressed as the mean±SEM. Differences between
two groups were assessed using an unpaired, two-tailed Student’s
t-test. Statistical comparisons of bacterial communities were per-
formed using a two-tailed Student’s t-test, treating variances as
equivalent.CorrelationswereanalyzedusingPearson’scorrelation.
Data were analyzed using GraphPad Prism version 5.00 for Win-
dows (GraphPad Software, San Diego, CA, USA) and JMP 8.0.1
(SAS Campus Drive,Cary,NC,USA). The results were considered
statistically signiﬁcant at P<0.05.
RESULTS
16S RRNA ANALYSIS OF GUT BACTERIAL POPULATIONS IN OBESE AND
DIABETIC MICE COMPARED TO LEAN MICE
Obese (ob/ob) mice and diet-induced obese mice are character-
ized by an altered composition of the gut microbiota (Ley et al.,
2005; Cani et al., 2007a,b; Turnbaugh et al., 2008, 2009). To
date, the composition of the gut microbiota of leptin-resistant
obese and type 2 diabetic (db/db) mice has never been reported.
The main differences between ob/ob and db/db mice are, ﬁrst,
in the leptin system, ob/ob mice are leptin-deﬁcient (they lack
the ob gene), whereas db/db mice are leptin-resistant (the CNS
has altered their “leptin receptors”), and, second, by phenotype,
both mice are hyperphagic, severely obese and have developed
fatty livers. However, db/db mice become type 2 diabetic early
after birth (a few weeks). This major difference between the two
models confers to db/db mice a clear advantage for investigat-
ing the role of the gut microbiota in this phenotype. The exact
composition of the gut microbiota in this model of obesity and
diabetes remains unknown. Therefore, we characterized the gut
microbiota composition of obese and diabetic db/db mice by
two complementary approaches: pyrosequencing and phyloge-
netic microarray analysis of the 16S rRNA genes isolated from
mouse cecal samples.
To explore bacterial diversity in cecal samples, we targeted the
16S rDNA hypervariable region V3. A total of 31,577 sequence
reads passed all quality control steps. We observed a signiﬁcant
increase of Proteobacteria (32,227%) in db/db mice compared
to lean mice (Table 1). The abundance of 10 genera was sig-
niﬁcantly affected by the genotype (Table 1). Interestingly, the
generaOdoribacter,Prevotella,andRikenella wereidentiﬁedexclu-
sively in the db/db group, whereas Enterorhabdus was identiﬁed
exclusively in lean mice (Table 1). Importantly, the abundance
of the Tannerella genus was increased by approximately 17,112%
in db/db mice. The representatives of the class Deltaproteobacte-
ria and the three genera of the phylum Bacteroidetes, all found
exclusively in db/db mice, are Gram-negative bacteria. Table A2
in Appendix shows the signiﬁcant differences in 96 phylotypes
(deﬁned at 97%-ID) enriched or depleted in db/db mice. Fur-
thermore, the results of the UniFrac analysis (Lozupone et al.,
2006) clearly showed that db/db cecal communities were more
similar to each other than to the communities of the control
lean mice (Figure 1A). Principal coordinate analysis (PCoA) of
UniFrac-based pairwise comparisons of community structures
revealed two clusters corresponding to the two dietary conditions
(Figure 1B). Importantly, we found a marked positive relation-
ship between the genus Oscillibacter and the expression of apelin
and APJ (r =0.88, P =0.0006, and r =0.87, P =0.0011, respec-
tively). We also performed deep and global microbiota analysis
using the MITChip, a high-throughput phylogenetic microarray
designed after the human counterpart (Rajilic-Stojanovic et al.,
2009), which was previously compared with 454 pyrosequenc-
ing (Claesson et al., 2009). The proﬁles of the cecal microbiota
were obtained based on the hybridization to over 3,500 oligonu-
cleotide probes and visualized the presence or absence of all
targeted operational taxonomic units (OTUs). MITChip analy-
sis revealed a clear separate clustering of the two treatment
groups (Figures 2C,D) that shared 81.2 (±2.6)% similarities
(Pearsonproduct-momentcorrelationcoefﬁcient).Weobserveda
lower relative and absolute abundance of the phyla Bacteroidetes
and Deferribacteres in db/db mice compared to the lean group
(Figures 2A,B,D), whereas we found a higher abundance of Fir-
micutes, Proteobacteria, and Fibrobacteres in db/db mice com-
pared to the lean group (Figures 2A,B,D). In accordance with
the pyrosequencing analysis, both groups were found to cluster
in a genotype-speciﬁc manner. In addition to speciﬁc changes
observed in the pyrosequencing analyses, we found several pre-
viously unidentiﬁed modiﬁcations at a lower taxonomic level,
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Table 1 | Taxa enriched or depleted in db/db mice.
Rank RDP classiﬁcation Abundance (percent
of total sequences)*
Change
in db/db
group**
(%)
P
value***
Lean db/db
Genus Actinobacteria; Actinobacteria; Coriobacteriales; Coriobacteriaceae; Enterorhabdus 0.019±0.008 0 LEAN [3] 0.0449
Genus Bacteroidetes; Bacteroidia; Bacteroidales; Porphyromonadaceae; Barnesiella 0.464±0.148 8.204±1.322 1668 0.0004
Genus Bacteroidetes; Bacteroidia; Bacteroidales; Porphyromonadaceae; Butyricimonas 0.091±0.022 0.006±0.006 −94 0.0061
Genus Bacteroidetes; Bacteroidia; Bacteroidales; Porphyromonadaceae; Odoribacter 0 0.150±0.040 DB [5] 0.0053
Genus Bacteroidetes; Bacteroidia; Bacteroidales; Porphyromonadaceae; Parabacteroides 0.756±0.122 0.235±0.070 −69 0.0060
Genus Bacteroidetes; Bacteroidia; Bacteroidales; Porphyromonadaceae;Tannerella 0.008±0.008 1.346±0.328 17112 0.0036
Family Bacteroidetes; Bacteroidia; Bacteroidales; Prevotellaceae 0 3.590±0.748 DB [5] 0.0014
Genus Bacteroidetes; Bacteroidia; Bacteroidales; Prevotellaceae; Prevotella 0 2.443±0.463 DB [5] 0.0008
Family Bacteroidetes; Bacteroidia; Bacteroidales; Rikenellaceae 4.262±0.802 9.061±0.798 113 0.0028
Genus Bacteroidetes; Bacteroidia; Bacteroidales; Rikenellaceae; Alistipes 4.262±0.802 9.042±0.794 112 0.0029
Genus Bacteroidetes; Bacteroidia; Bacteroidales; Rikenellaceae; Rikenella 0 0.019±0.008 DB [3] 0.0409
Family Firmicutes; Clostridia; Clostridiales; Ruminococcaceae 7 .259±1.231 14.029±2.216 93 0.0283
Genus Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Oscillibacter 5.831±0.858 10.539±1.482 81 0.0251
Phylum Proteobacteria 0.006±0.006 2.036±0.570 32227 0.0074
Class Proteobacteria; Deltaproteobacteria 0 1.227±0.292 DB [5] 0.0030
*Data are the mean±SE.
**Change in average taxa abundance in db/db mice subset when compared to the lean mice subset. Only changes associated withaPv alue<0.05 are given.
***P value was determined by a two-tailed Student’s t-test with equal variance.
[Number] following LEAN or DB corresponds to the number of mice in the indicated subset in which the given phylotype was found.
especially the absolute and relative increase of Prevotella spp. (not
shown).
OBESE AND DIABETIC MICE EXHIBITED A HIGHER ENDOCANNABINOID
SYSTEM TONE IN ADIPOSE TISSUE
We have previously demonstrated that the gut microbiota con-
tribute to the regulation of eCB system tone in adipose tissue
in both physiological and pathological situations (Muccioli et al.,
2010). In addition, obesity is characterized by higher eCB system
toneinbothhumansandrodents(Engelietal.,2005;Bluheretal.,
2006; Matias et al., 2006; Cote et al., 2007; D’Eon et al., 2008;
Starowicz et al.,2008;Izzo et al.,2009;Muccioli et al.,2010). Con-
sistentwiththeseﬁndings,wediscoveredthatdb/db mice,fedwith
astandarddiet,exhibitedanincreasedeCBsystemtone(AEAlevels
and mRNA expression). Anandamide (AEA; Devane et al., 1992)
isanendogenousCB1 andCB2 ligand.Herewefoundasigniﬁcant
increase in AEA levels (about 50%) in adipose tissue (Figure 3A).
Inaccordancewiththisresult,NAPE-PLDandCB1 mRNAexpres-
sion were signiﬁcantly increased, whereas mRNA expression for
theAEA-degradingenzymeFAAHwasreduced(Figures3B,C,D).
Note that expression of monoacylglycerol lipase (MGL),the main
enzyme that degrades endocannabinoid 2-arachidonoylglycerol
(2-AG), tended to be higher in the adipose tissue of db/db mice
(Figure 3E), which is consistent with the reduced 2-AG levels
observed in adipose tissue (Figure 3F). Altogether, these data
demonstrate for the ﬁrst time that db/db mice display an altered
eCB system tone in adipose tissue, and more speciﬁcally, they
display increased signaling for the endocannabinoid AEA.
INCREASED APELIN AND APJ EXPRESSION IN THE ADIPOSE TISSUE OF
OBESE AND DIABETIC MICE
Recent evidence suggests that, in pathophysiological conditions
(obesity and type 2 diabetes), the peripheral apelinergic sys-
tem seems to be deregulated (Dray et al., 2008, 2010; Duparc
et al., 2011a). To date, the mechanisms of regulation of apelin
and APJ expression in the adipose tissue of obese and diabetic
mice are not fully understood. Therefore, we investigated ape-
linergic system tone in this model and found that apelin and
APJ mRNA levels were signiﬁcantly increased by two- and three-
fold, respectively, in the adipose tissue of db/db mice compared
to lean littermates (Figures4A,B). Plasma apelin was increased by
approximately30%,butdidnotreachsigniﬁcance(db/db:7.1±1,
lean: 5.8±0.8pg/ml).
Interestingly, we found several positive and negative correla-
tions between the abundance of speciﬁc bacteria and apelin/APJ
expression,suggestingapotentialrelationshipbetweenspeciﬁcgut
bacteria and the regulation of the apelinergic system (Table 2).
INCREASED LOW-GRADE INFLAMMATION IN THE ADIPOSE TISSUE OF
DB/DB MICE
We have previously demonstrated that the higher eCB system
tone observed in the adipose tissue of obese and diabetic mice
was directly dependent on low-grade inﬂammatory tone (Mucci-
oli et al., 2010). In addition, db/db mice are considered a widely
used model to investigate the metabolic features associated with
obesity and type 2 diabetes. These mice are characterized by
a low-grade inﬂammatory tone with higher plasma LPS levels
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FIGURE 1 |Analysis of gut bacterial communities by 16S
rRNA pyrosequencing from obese diabetic mice or lean mice.
(A) Clustering of mouse cecal microbial communities in the two
tested groups based on unweighted UniFrac analysis and 97%-ID
phylotypes. Red indicates the diabetic mice (db/db), and blue
indicates the lean mice. Branch length represents the distance
between environments in UniFrac units, indicated by the scale bar
(n=5/group). (B) PCoA analysis based on unweighted (presence/absence)
UniFrac analysis and 97%-ID phylotypes. Each symbol (ﬁlled circle or ﬁlled
square) representing a single sample is colored according to dietary
conditions: red corresponds to db/db, and blue corresponds to lean
(n=5/group).
and signiﬁcantly higher plasma levels of IL-1β, IL-6, TNF-α, and
INF-γ (Brun et al., 2007). Moreover, the assessment of adipose
tissue inﬂammation revealed an increased number of crown-
like structures corresponding to proinﬂammatory macrophages
that are F4/80 and CD11c positive (Mihara et al., 2010; Hell-
mann et al., 2011). Consistent with numerous previous reports
investigating meta-inﬂammation in this model, we found a sig-
niﬁcant increase in both inﬂammation and macrophage inﬁl-
tration markers in our db/db mice. The markers investigated in
this study (IL-1, Monocyte Chemoattractant Protein-1 (MCP-1),
F4/80,CD11c,and CD68 mRNA expression) were all signiﬁcantly
increased by 50 to 400% in db/db mice compared to lean mice
(Figures 5A–E).
BOTH THE ECB SYSTEM AND LOW-GRADE INFLAMMATION
PARTICIPATE IN THE REGULATION OF ADIPOSE TISSUE APELIN AND
APJ EXPRESSION
Understanding the molecular mechanisms responsible for the
alteredapelinergicsystemisessentialtoﬁndputativenoveltargets
for modulating adipose tissue metabolism. We have previously
shown that both the low-grade inﬂammatory tone and the higher
eCB system tone observed in obesity and related disorders could
belinkedtogutmicrobiotacomposition(Canietal.,2009;Mucci-
olietal.,2010;CaniandDelzenne,2011).Moreimportantly,ithas
been previously demonstrated that inﬂammation regulates both
apelin and APJ mRNA expression (Daviaud et al., 2006; Melgar-
Lesmes et al., 2011). In addition, our in vivo experiments and
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FIGURE2|P h ylogenetic microarray analysis of gut bacterial
communities from obese diabetic mice or lean mice. (A) Percentages of
each community contributed by the indicated level 1 bacterial groups. (B)
PCoA analysis based on MITChip phylogenetic ﬁngerprints of the gut
microbiota from the cecal contents of db/db and lean mice. (C) Hierarchical
clustering visualizing the similarities of the phylogenetic MITChip ﬁngerprints.
Samples were hierarchically clustered based on the Pearson correlation. (D)
Relative abundance of different bacterial classes expressed as the percentage
of total probe signals (n=5/group). *P <0.05, **P <0.01 determined by a
two-tailed Student’s t-test.
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FIGURE 3 | Higher endocannabinoid system tone in the adipose tissue
of db/db mice. (A) AEAtissue content (% of lean), (B) NAPE-PLD, (C) CB1,
(D) FAAH; (E) MGL mRNA expression, and (F) 2-AG tissue content (% of
lean) measured in adipose tissue. Mean±SEM, n=6/group, *P <0.05
determined by a two-tailed Student’s t-test.
multiplecorrelationanalysessuggestalinkbetweeninﬂammation
and the regulation of the apelinergic system (Figure A1). How-
ever, the causal link between these parameters and the regulation
of apelin and APJ expression in the adipose tissue remain to be
demonstrated.
Given the difﬁculty of deciphering the impact of low-grade
inﬂammation (i.e., plasma LPS or cytokines) and eCB system
tone on the apelinergic system in vivo, we decided to explore
these mechanisms on in vitro cultured adipose tissue explants.
Of note, these explants came from healthy, lean C57BL/6 mice,
allowing us to investigate physiological-like or pathological-like
situations, that is, eCB system tone modulation with or without a
concomitant inﬂammatory situation.
Here, we found that the activation of the eCB system by a
cannabinoid receptor agonist (HU-210) signiﬁcantly decreased
FIGURE 4 | Increased apelin andAPJ mRNA expression in the adipose
tissue of db/db mice. (A) Apelin and (B) APJ mRNA expression measured
in adipose tissue. Mean±SEM, n=6/group, *P<0.05 determined by a
two-tailed Student’s t-test.
apelin andAPJ mRNA expression (Figures6A,B). In line with the
results obtained using the cannabinoid receptor agonist in vitro,
in lean wild-type mice, we found that in vivo inhibition of AEA
degradation by the administration of a potent FAAH inhibitor
(URB597; Kathuria et al.,2003) signiﬁcantly decreased apelin and
APJ mRNA expression (Figure A2). These data support the idea
that the eCB system down-regulates the apelinergic system in
physiological situations. However, we found that low-dose LPS
signiﬁcantly increased these two markers. More importantly, the
adipose tissue explants treated with both cannabinoid receptor
agonist and LPS exhibited a signiﬁcant increase in apelin and
APJ mRNA expression (Figures 6A,B). Altogether, this set of
experiments suggests that both the eCB system and low-grade
inﬂammatory tone contribute to the regulation of apelin and APJ
inadiposetissue.Interestingly,concomitantstimulationwitheCB
agonist and LPS resulted in up-regulation of the apelinergic sys-
tem. In parallel, we found that two key inﬂammatory markers
(IL-1 and TNF-α) were similarly up-regulated following LPS-eCB
treatment (Figures 6C,D). These data further conﬁrm that (i)
both the eCB system and low-grade inﬂammation might be over-
active during obese and type 2 diabetic situations, and (ii) that
LPS and/or inﬂammation act as a master switch in the regulation
of the apelinergic system.
DISCUSSION
This study provides new evidence for an altered gut microbiota
in type 2 diabetes,independent of fat feeding. Indeed,we demon-
strate that the gut microbial community is profoundly impacted
by genotype and not necessarily diet because db/db mice, com-
pared to their littermates, exhibited a profound alteration of the
gutmicrobiotacomposition.Inaddition,wefoundthatsometaxa
are present or rather absent in diabetic mice compared to their
lean littermates. These important ﬁndings question the potential
impact of these bacteria in the onset of the phenotypic alterations
characterizingthismodel.Althoughthemicrobiotaanalysisrelied
on complementary technologies and classiﬁcation methods, data
showed similar patterns of speciﬁc clustering of bacterial com-
munities.We observed a decrease in the abundance of the phylum
BacteroidetesandanincreaseofFirmicutes.Importantly,wefound
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Table 2 | Correlations between changes in the abundance of speciﬁc
bacteria and adipose tissue apelin orAPJ mRNA levels.
rp -Value
Apelin
Acholeplasma et rel. 0.73 0.0162
Aerococcus urinaeequi et rel. 0.89 0.0005
Atopobium 0.70 0.0255
Bryantella et rel. 0.68 0.0296
Butyrivibrio crossotus et rel. 0.67 0.0344
Catenibacterium 0.66 0.0364
Cl. lactifermentans et rel. 0.75 0.0120
Cl. perfringens et rel. −0.84 0.0024
Dialister et rel. 0.81 0.0043
Eggerthella et rel. −0.65 0.0403
Eub. hallii et rel. 0.74 0.0135
Helicobacter −0.72 0.0181
Lachnospira pectinoschiza et rel. 0.76 0.0110
L. salivarius et rel. −0.64 0.0478
Mucispirillum schaedleri et rel. −0.69 0.0276
Porphyromonas asaccharolytica et rel. −0.80 0.0057
Prevotella −0.68 0.0319
R. obeum et rel. 0.76 0.0106
Sporobacter termitidis et rel. 0.89 0.0005
Unc. Porphyromonadaceae −0.86 0.0016
APJ
Acholeplasma et rel. 0.74 0.0148
Aerococcus urinaeequi et rel. 0.84 0.0023
Atopobium 0.68 0.0319
Bryantella et rel. 0.71 0.0206
Butyrivibrio crossotus et rel. 0.68 0.0321
Catenibacterium 0.72 0.0197
Cl. difﬁcile et rel. 0.65 0.0416
Cl. lactifermentans et rel. 0.66 0.0363
Cl. perfringens et rel. −0.79 0.0070
Dialister et rel. 0.79 0.0065
Eub. hallii et rel. 0.76 0.0116
Fibrobacter succinogenes et rel. 0.65 0.0407
Helicobacter −0.76 0.0113
Labrys methylaminiphilus et rel. 0.70 0.0236
Lachnospira pectinoschiza et rel. 0.72 0.0179
L. gasseri et rel. 0.67 0.0341
L. salivarius et rel. −0.67 0.0333
Porphyromonas asaccharolytica et rel. −0.76 0.0101
R. obeum et rel. 0.64 0.0479
Sporobacter termitidis et rel. 0.85 0.0017
Unc. Porphyromonadaceae −0.86 0.0013
a dramatic increase of Proteobacteria following the pyrosequenc-
ing method. Moreover, ten genera whose abundance was signiﬁ-
cantly affected by the genotype have been identiﬁed. Interestingly,
we identiﬁed several taxa of Gram-negative bacteria at signiﬁ-
cantly higher frequencies or exclusively in db/db mice. Because
LPS from Gram-negative bacteria triggered low-grade inﬂamma-
tion and stimulated apelin and APJ expression, we postulate that
these speciﬁc changes contributed to the phenotype observed in
db/db mice compared to their lean counterparts. In addition to
FIGURE 5 | Increased inﬂammatory markers in the adipose tissue of
db/db mice. (A) IL -1, (B) F4/80, (C) MCP-1, (D) CD11c, and (E) CD68
mRNA expression measured in adipose tissue. Mean±SEM, n=6/group,
*P<0.05 determined by a two-tailed Student’s t-test.
the putative higher content of LPS within the intestinal lumen, it
has been previously shown that db/db mice are characterized by
greater intestinal inﬂammation and gut permeability (Brun et al.,
2007; Duparc et al., 2011b). Therefore, in addition to the dys-
function of the leptin action characterizing this mouse model,we
propose that the shift in the gut microbial community observed
also contributed to the development of the complex phenotype
found in db/db mice. Nevertheless, given the complexity of these
modiﬁcations and the number of correlations found, the direct
association between one or more speciﬁc taxa and the changes
affecting host physiology remain to be investigated. Hence, fur-
ther work is required to understand the functional links between
the metabolic/catabolic activities of gut bacteria and their impact
on host metabolism. For instance,it would be of interest to inves-
tigate this genetic model in a germ-free situation to identify the
speciﬁcimpactof thegutmicrobesontheonsetof type2diabetes.
Importantly, when we compared the classiﬁcation results from
pyrosequencingtothoseobtainedfromphylogeneticmicroarrays,
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FIGURE 6 |The eCB system down-regulates LPS-induced inﬂammation
(IL-1 andTNF-α mRNA expression) and the apelinergic system (apelin
andAPJ mRNA expression) in adipose tissue explant cultures. mRNA
expression levels of (A) Apelin, (B) APJ, (C) IL -1, and (D)TNF-α in cultured
adipose tissue explants from lean mice exposed to vehicle (CT), LPS (LPS) or
cannabinoid receptor agonist HU-210 (HU; 100 nM) alone or in combination
with LPS (100 ng.ml, LPS-HU) for 24h. * indicates P <0.05 for the drug
effect; by a two-tailed Student’s t-test.
we observed more differences attributed to a deeper analysis of
the phylogenetic microarrays (<0.1% of the community; Rajilic-
Stojanovic et al., 2009) than pyrosequencing. Recently the impact
of use of different primers was assessed by 454 pyrosequencing
and could impact the microbial proﬁling (van den Bogert et al.,
2011), off note, deep pyrosequencing and phylogenetic microar-
rays provided similar biological conclusions,although the classiﬁ-
cation may be different from that in previously reported systems
(Claesson et al., 2009).
This study also provided novel mechanisms involving the
important roles of the eCB and low-grade inﬂammatory tone in
the regulation of one speciﬁc adipokine and its receptor, namely,
apelin and APJ. Hence, multiple correlation analyses suggest that
speciﬁc gut microbes positively or negatively correlate with apelin
and APJ mRNA. This study also supports the interest of com-
bining high-throughput culture-independent approaches with
physiological assessments to deﬁne the relationships between gut
microbial communities and host metabolism. Nevertheless, given
the complexity of these biological systems, the direct association
between one or more bacterial groups and the changes affecting
host physiology remain to be conﬁrmed.
During the last years, numerous studies have demonstrated
a clear relationship between energy metabolism and peripheral
apelinaction.Underpathophysiologicalconditions,theperipheral
apelinergicsystemseemstobederegulated(Drayetal.,2008,2010;
Duparc et al., 2011a). While some researchers found that levels of
plasma apelin in humans and mice were increased in obese dia-
betes (Heinonen et al., 2005; Dray et al., 2008) and in the insulin
resistance state (Soriguer et al., 2009), others demonstrated that
plasma apelin was reduced in type 2 diabetes patients (Erdem
et al., 2008). Recently, it has been highlighted that the severity of
insulinresistancemightinﬂuencetheregulationof apelinandAPJ
expression (Dray et al.,2010).
In this study,we ﬁrst demonstrated the presence of an increase
in eCB system tone (higher AEA levels, NAPE-PLD, and CB1
expression and lower FAAH expression) in the adipose tissue
of db/db mice. Here we show for the ﬁrst time that AEA lev-
els are increased in adipose tissue and are in accordance with
our previous ﬁndings (Muccioli et al., 2010). In parallel, we
found that both apelin and APJ expression were signiﬁcantly
increased.Byusingmultiplecorrelationanalyses,weobservedvery
strong relationships between the eCB system and the apelinergic
system, supporting the potential implication of the eCB system
in apelinergic tone. However, db/db mice were also character-
ized by a higher inﬂammatory tone (Brun et al., 2007), which
is, according to our results, positively and signiﬁcantly corre-
lated with apelin/APJ. Given that db/db mice also exhibited
better eCB system tone and inﬂammation, we investigated the
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direct impact of the endocannabinoids. To clarify this issue, we
increased endogenous AEA levels in the adipose tissue of lean
mice following the inhibition of FAAH (Muccioli et al., 2010),
the main AEA-degrading enzyme (Muccioli, 2010). Strikingly,
we found that this procedure signiﬁcantly decreased apelin and
APJ expression. Similarly to these in vivo data, the stimulation
of adipose tissue explants with cannabinoid agonist profoundly
reduced the expression of apelin and APJ. Furthermore, know-
ing that db/db mice developed a low-grade inﬂammatory tone,
possibly linked to gut microbiota-derived LPS, we investigated
the role of LPS in the regulation of these peptides. Interest-
ingly, we demonstrated that LPS directly increased apelinergic
system tone in adipose tissue. We also found that LPS treatment
completely counteracted the eCB-dependent down-regulation of
apelin and APJ. Taken together, all these data strongly support
the concept that both systems are implicated in the regulation
of apelinergic tone. However, both our in vivo and in vitro data
point to inﬂammation as a master control in this cross-talk.
Based on these data, we postulate that, in physiological condi-
tions, eCB system tone participates in the down-regulation of
the apelinergic system, whereas in pathological conditions, the
low-grade inﬂammatory tone acts as a master switch to increase
both eCB system tone and the apelinergic system. Although
our data relied on different regulatory mechanisms (eCB tone
and metabolic endotoxemia), both are clearly associated with
gut microbiota composition (Cani and Delzenne, 2011). Thus,
understanding the complexity of gut microbiota is increasingly
important for deciphering potential interactions between hosts
and microbes.
In conclusion, we have demonstrated that the eCB and low-
grade inﬂammatory tone are closely involved in the regulation of
apelin and APJ expression in adipose tissue. Moreover, we found
that genetic obese and type 2 diabetic mice harbored profound
changes in their gut microbiota compositions compared to their
lean counterparts. Although we found strong positive and neg-
ative relationships between speciﬁc bacteria and the apelinergic
system, the exact implications of several bacteria for shaping the
phenotype of these mice remain to be studied.
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APPENDIX
FIGUREA1 | Multiple correlation analyses between the apelinergic system and inﬂammation. Pairwise correlations between F4/80 or IL -1 and apelin
(A,B) or APJ (C,D) mRNA expression measured in the adipose tissue of db/db mice. Insets in each graph depict Pearson’s correlation value of the coefﬁcient (r)
and P values.
FIGUREA2 | FAAH inhibition decreasedApelin andAPJ mRNA
expression in the adipose tissue of mice. Apelin and APJ mRNA
expression measured in the adipose tissue of lean mice treated with a
single dose of the FAAH inhibitor URB. Mean±SEM, n=6/group,
*P<0.05 determined by a two-tailed Student’s t-test.
TABLEA1 | Sequencing statistics for 10 cecal microbiomes.
Primer barcode Number of ﬁltered sequences Mouse ID Group
692 3470 1 db/db
693 2754 2 db/db
694 3077 3 db/db
695 3038 4 db/db
696 3564 5 db/db
697 2558 6 lean
698 3314 7 lean
699 2920 8 lean
700 3707 9 lean
701 3175 10 lean
Reverse PCR primers contained barcode sequences described by Hamady et al.
(2008).
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